Cathepsin A Enhances BCL-2 Stability to Promote Hepatocellular Carcinoma Cell Growth

ZHANG Xiangwen, TANG Wenbin, CHEN Wei, YANG Daifei, LIU Zhengxin, LI Zhuan

Journal of Hunan Normal University(Medical Science) ›› 2026, Vol. 23 ›› Issue (2) : 9-16.

PDF(4993 KB)
PDF(4993 KB)
Journal of Hunan Normal University(Medical Science) ›› 2026, Vol. 23 ›› Issue (2) : 9-16.
Basic Medicine

Cathepsin A Enhances BCL-2 Stability to Promote Hepatocellular Carcinoma Cell Growth

  • ZHANG Xiangwen, TANG Wenbin, CHEN Wei, YANG Daifei, LIU Zhengxin, LI Zhuan
Author information +
History +

Abstract

Objective To investigate the expression characteristics of cathepsin A (CTSA) in hepatocellular carcinoma (HCC), its effects on tumor cell growth, and its association with BCL-2 protein stability. Methods CTSA expression in HCC and its relationship with clinicopathological features/prognosis were analyzed using The Cancer Genome Atlas (TCGA) dataset. CTSA expression in HCC tissues and cells was examined by quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). CTSA knockdown was performed in Huh7 and HepG2 cells. Cell proliferation was assessed by Cell Counting Kit-8 (CCK-8) and colony formation assays, and apoptosis was evaluated by flow cytometry. A subcutaneous xenograft model was established to validate the in vivo effect. Co-immunoprecipitation was used to determine the interaction between CTSA and BCL-2. Cycloheximide (CHX) chase combined with protein quantification was conducted to assess BCL-2 degradation dynamics. Results Database analysis and experimental validation showed that CTSA was upregulated in HCC. CTSA knockdown inhibited HCC cell proliferation, reduced clonogenic capacity, and promoted apoptosis (flow cytometry showed an increase in apoptosis rate from 4.2% to 14.7%). In the subcutaneous xenograft model, tumor volume and weight were reduced in the CTSA knockdown group. Mechanistically, CTSA interacted with BCL-2 and affected its protein stability, thereby regulating BCL-2-related anti-apoptotic processes. Conclusion Our study shows that CTSA is highly expressed in HCC and correlates with poor prognosis. CTSA knockdown inhibits hepatocellular carcinoma cell proliferation and promotes apoptosis, partly by stabilizing BCL-2 and maintaining anti-apoptotic signaling.

Key words

cathepsin A / hepatocellular carcinoma / cell proliferation / BCL-2 / protein stability

Cite this article

Download Citations
ZHANG Xiangwen, TANG Wenbin, CHEN Wei, YANG Daifei, LIU Zhengxin, LI Zhuan. Cathepsin A Enhances BCL-2 Stability to Promote Hepatocellular Carcinoma Cell Growth[J]. Journal of Hunan Normal University(Medical Science). 2026, 23(2): 9-16

References

[1] SIEGEL RL, GIAQUINTO AN, JEMAL A.Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] GILLES H, GARBUTT T, LANDRUM J.Hepatocellular carcinoma[J]. Crit Care Nurs Clin North Am, 2022, 34(3): 289-301.
[3] ZAMYATNIN AA, GREGORY LC, TOWNSEND PA, et al.Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy[J]. Expert Opin Ther Targets, 2022, 26(11): 963-977.
[4] ERIKSSON I, ÖLLINGER K.Lysosomes in cancer-at the Crossroad of good and evil[J]. Cells, 2024, 13(5): 459.
[5] 吴洁, 张婷婷, 李珂. 组织蛋白酶A维持肿瘤干细胞性状促进三阴性乳腺癌发生发展[J]. 药学学报, 2024, 59(7): 2020-2029.
[6] WANG H, XU F, YANG F, et al.Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 14611.
[7] VOGLER M, BRAUN Y, SMITH VM, et al.The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy[J]. Signal Transduct Target Ther, 2025, 10(1): 91.
[8] KALONI D, DIEPSTRATEN ST, STRASSER A, et al.BCL-2 protein family: attractive targets for cancer therapy[J]. Apoptosis, 2023, 28(1-2): 20-38.
[9] XU J, DONG X, HUANG DCS, et al.Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers[J]. Cancers, 2023, 15(20): 4957.
[10] TANG GLQ, LAI JXH, PERVAIZ S.Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches[J]. Haematologica, 2024, 109(1): 33-43.
[11] TOSS MS, MILIGY IM, HAJ-AHMAD R, et al.The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ[J]. Histopathol, 2019, 74(7): 1025-1035.
[12] HU B, ZHU X, LU J.Cathepsin A knockdown decreases the proliferation and invasion of A549 lung adenocarcinoma cells[J]. Mol Med Rep, 2020, 21(6): 2553-2559.
[13] NI S, WENG W, XU M, et al.Mir-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA[J]. Onco Targets Ther, 2018, 11: 3835-3845.
[14] PALABIYIK AA.The role of Bcl-2 in controlling the transition between autophagy and apoptosis[J]. Mol Med Rep, 2025, 32(1): 172.
[15] PEMBERTON JM, POGMORE JP, ANDREWS DW.Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins[J]. Cell Death Differ, 2021, 28(1): 108-122.
[16] VAFA A, RAIS B, AFROZ N, et al.The BCL-2-tumor microenvironment axis: mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming[J]. Crit Rev Oncol Hematol, 2026, 217: 105005.
PDF(4993 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉